Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2025.04.03

Sai Life Sciences sets up Peptide Research Center in India

Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), has inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad, India.
Announcing the launch, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “As the pharmaceutical industry evolves from small molecules to emerging modalities like peptides, we are expanding our capabilities to stay ahead. Our new Peptide Research Center reflects this commitment—designed to meet the growing demand for complex peptide synthesis and conjugation. With this investment, we reinforce our role as a trusted partner in advancing next-generation therapeutics.”
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates. The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics.

Maneesh Pingle, Head of Discovery Services, said: “The demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects. At Sai Life Sciences, we have a seasoned team of scientists with years of experience successfully delivering peptide discovery and development projects. Combined with our expanding capabilities, this expertise positions us strongly to support our clients’ evolving needs as they advance peptide therapies across diverse therapeutic areas."

The new Peptide Research Center will be integrated with Sai Life Sciences’ end-to-end discovery services, spanning synthetic and medicinal chemistry, biology, DMPK, and toxicology. This holistic approach ensures seamless transitions across different stages of drug discovery, accelerating timelines and enhancing success rates for peptide-based drug development.

By combining deep expertise, cutting-edge technology, and an integrated approach, Sai Life Sciences strengthens its commitment to supporting global clients in advancing innovative peptide therapeutics.

Share article

More News

2025.02.07

Sai Life Sciences headquarters, symbolizing innovation and growth, featured in a blog post about the company's strong quarterly report performance.

Sai Life Sciences Limited reports robust quarterly results

Revenue grows by 15%; Net Profit up 36% year-on-year Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, Contract Research and Development Organization (CRDMO) today announced its financial results for the third quarter and nine months ended December 31, 2024. Financial Performance: Particulars (₹ crores) Q3FY25 Q3FY24 YoY% 9MFY25 9MFY24 YoY% Revenue […]
Read more

2025.01.01

Before and after comparison of the historic Manchirevula stepwell restoration by Sai Life Sciences, showcasing transformation from a neglected site to a well-maintained water body near a temple.

Sai Life Sciences completes restoration of historic Manchirevula stepwell

As part of its Corporate Social Responsibility (CSR) initiative, Sai Life Sciences, in collaboration with the Society for Advancement of Human Endeavours (SAHE), completed the restoration of the historic stepwell dating back to the 17th century at the Sri Venugopala Swamy temple premises, located in Manchirevula, Hyderabad. The Manchirevula Stepwell Restoration Project was undertaken with […]
Read more

2024.10.28

Advanced manufacturing facility at Sai Life Sciences, showcasing state-of-the-art equipment and quality control, featured in a blog post about receiving Establishment Inspection Reports (EIRs) from the USFDA.

Sai Life Sciences receives EIRs from USFDA for India R&D & Manufacturing facilities

Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], announced that it has received Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA) for its R&D (Unit II, Hyderabad), and Manufacturing (Unit IV, Bidar) sites in India. The General Good Manufacturing Practices (GMP) audit was conducted at the […]
Read more

2024.10.07

Sai Life Sciences' eco-friendly campus with green landscaping and modern architecture at sunset, featured in a blog post about the company's 2024 Sustainability Report

Sai Life Sciences releases Sustainability Report 2024

Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], published its Sustainability Report for 2023-2024. Aligned with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, this fifth edition of the Sustainability Report is based on the theme, ‘Synergising Sustainability, Performance and Growth.’ The full report can be read here. Making […]
Read more

2024.08.09

Sai Life Sciences scientist accessing a -40.2°C ultra-low temperature storage unit as part of the advanced Compound Management process, enhanced by the in-house CORAL software application.

Sai Life Sciences elevates Compound Management process with in-house software application, CORAL

Compound management is a vital function in pharmaceutical research. A streamlined environment can bring significant value to the process in the form of productivity and efficiency. Recognizing the importance of this function, we have made our Compound Management suite for Discovery services smarter with the introduction of an in-house software application, Compound Organization and Registration […]
Read more